136
Participants
Start Date
July 1, 2024
Primary Completion Date
May 1, 2026
Study Completion Date
May 1, 2030
Toripalimab plus Anlotinib
For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
Toripalimab
For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
Taizhou Hospital
OTHER